Randomized, open-label trial of primaquine against vivax malaria relapse in indonesia

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1128-1135

  Sutanto, Inge ^a   Tjahjono, Bagus ^b   Basri, Hasan ^c   Robert Taylor, W ^c   Putri, Fauziah A ^c   Meilia, Rizka A ^c   Setiabudy, Rianto ^a   Nurleila, Siti ^c   Ekawati, Lenny L ^c   Elyazar, Iqbal ^c   Farrar, Jeremy ^c,d   Sudoyo, Herawati ^e   Kevin Baird, J ^c,d  

^a UNIVERSITY OF INDONESIA   (Indonesia)

^b Municipal Health Service   (Indonesia)

^c OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e EIJKMAN INSTITUTE FOR MOLECULAR BIOLOGY   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

ARTESUNATE; DIHYDROARTEMISININ PLUS PIPERAQUINE; MALAFREE; PRIMAQUINE; QUININE; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHLORIDE BLOOD LEVEL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG EFFICACY; ERYTHROCYTE COUNT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEARING IMPAIRMENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INDONESIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; NONHUMAN; OPEN STUDY; PLASMODIUM VIVAX MALARIA; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; SINGLE DRUG DOSE; SODIUM BLOOD LEVEL; TINNITUS; TREATMENT DURATION;

ADULT; ANTIMALARIALS; ARTEMISININS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; INDONESIA; MALARIA; MALARIA, VIVAX; MALE; MILITARY PERSONNEL; PLASMODIUM VIVAX; PRIMAQUINE; QUININE; QUINOLINES; RECURRENCE;

EID: 84874098744     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01879-12     Document Type: Article

References (43)

1. Mendis K, Sina BJ, Marchesini P, Carter R. 2001. The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 64(1-2 Suppl):97- 106.
2. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. 2007. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 77(6 Suppl):79-87.
3. Baird JK. 2007. Neglect of Plasmodium vivax malaria. Trends Parasitol. 23:533-539.
4. Guerra CA, Howes RE, Patil PA, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI. 2010. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl. Trop. Dis. 4:e774. doi:10.1371/journal.pntd.0000774.
5. Baird JK. 2013. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin. Microbiol. Rev. 26:36 -57.
6. White NJ. 2011. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar. J. 10:297.
7. Baird JK. 2009. Resistance to therapies for infection by Plasmodium vivax. Clin. Microbiol. Rev. 22:508 -534.
8. Setiawan B. 2010. Ministry of Health Indonesia: current malaria management guideline 2009. Acta Med. Indones. 42:258 -261.
9. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PM, Laihad F, Anstey NM, Tjitra E, Price RN. 2007. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and post-treatment prophylaxis against multidrug resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin. Infect. Dis. 44:1067-1074.
10. Karunajeewa HA, Mueller I, Senn M, Lin E, Law I, Gomorrai PS, Oa O, Griffin S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, Siba P, Ilett KF, Davis TM. 2008. A trial of combination therapies in children from Papua New Guinea. N. Engl. J. Med. 359:2545-2557.
11. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL. 1955. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J. Lab. Clin. Med. 46:301-306.
12. Baird JK. 2011. Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob. Agents Chemother. 55:1827-1830.
13. Baird JK. 2008. Real world therapies and the problem of vivax malaria. N. Engl. J. Med. 359:2601-2603.
14. Imwong M, Boel ME, Pagornrat W, Pimanpanarak M, McGready R, Day NP, Nosten F, White NJ. 2012. The first Plasmodium vivax relapses of life are usually genetically homologous. J. Infect. Dis. 205:680-683.
15. Baird JK, Hoffman SL. 2003. Primaquine therapy for malaria. Clin. Infect. Dis. 37:1659 -1667.
16. Baird JK. 1998. Primaquine as anti-relapse therapy for Plasmodium vivax. Trans. R. Soc. Trop. Med. Hyg. 92:687.
17. Gogtay NJ, Desai S, Kamtekar KD, Kadam KS, Dalvi SS, Kshirsagar NA. 1999. Efficacies of the 5- and 14-day regimens in the prevention of relapses in Plasmodium vivax infections. Ann. Trop. Med. Parasitol. 93:809-812.
18. Yadav RS, Ghash SK. 2002. Radical curative efficacy for five-day regimen of primaquine for treatment of Plasmodium vivax malaria in India. J. Parasitol. 88:1042-1044.
19. Elyazar IR, Gething PW, Patil AP, Rogayah H, Kusriastuti R, Wismarini DM, Tarmizi SN, Baird JK, Hay SI. 2011. Plasmodium falciparum endemicity in Indonesia in 2010. PLoS One 6:e21315. doi:10.1371/journal .pone.0021315.
20. Elyazar IR, Gething PW, Patil AP, Rogayah H, Sariwati E, Palupi NW, Tarmizi SN, Kusriastuti R, Baird JK, Hay SI. 2012. Plasmodium vivax endemicity in Indonesia in 2010. PLoS One 7:e37325. doi:10.1371/journal .pone.0037325.
21. Ohrt C, Richie TL, Widjaja H, Shanks GD, Fitriadi J, Fryauff DJ, Handschin J, Tang D, Sandjaja B, Tjitra E, Hadiarso L, Watt G, Wignall FS. 1997. Mefloquine compared with doxycycline for the prophylaxis of malaria in Indonesian soldiers. A randomized, double-blind, placebocontrolled trial. Ann. Intern. Med. 126:963-972.
22. Taylor WR, Richie TL, Fryauff DJ, Picarima H, Ohrt C, Tang D, Braitman D, Murphy GS, Widjaja H, Tjitra E, Ganjar A, Jones TR, Basri H, Berman J. 1999. Malaria prophylaxis using azithromycin: a doubleblind, placebo-controlled trial in Irian Jaya, Indonesia. Clin. Infect. Dis. 28:74-81.
23. Tsiatis AA, Zang D. 2009. Statistical principles of clinical trials. Department of Statistics, North Carolina State University, Raleigh, NC.
24. World Health Organization. 2010. Guidelines for the treatment of malaria, 2nd ed, p 166-187. World Health Organization, Geneva, Switzerland.
25. Schwartz E, Regev-Yochay G, Kurnik D. 2000. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 62:393-395.
26. McNamara DT, Kasehagen LJ, Grimberg BT, Cole-Tobian J, Collins WE, Zimmerman PA. 2006. Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay. Am. J. Trop. Med. Hyg. 74:413- 421.
27. Baird JK, Wiady I, Fryrauff DJ, Sutanihardja MA, Leksana B, Widjaya H, Kysdarmanto Subianto B. 1997. In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am. J. Trop. Med. Hyg. 56:627- 631.
28. Myint HY, Ashely EA, Day NP, Nosten F, White NJ. 2007. Efficacy and safety of dihydroartemisinin-piperaquine. Trans. R. Soc. Trop. Med. Hyg. 101:858-866.
29. Hale BR, Owusu-Agyei S, Fryauff DJ, Koram KA, Adjuik M, Oduro AR, Prescott WR, Baird JK, Nkrumah F, Richie TL, Franke ED, Binka FN, Horton J, Hoffman SL. 2003. A randomized double-blind placebocontrolled dose-ranging trial of tafenoquine for weekly prophylaxis against Plasmodium falciparum. Clin. Infect. Dis. 36:541-549.
30. Morgenstern H, Kleinbaum DG, Kupper LL. 1980. Measures of disease incidence in epidemiological research. Int. J. Epidemiol. 9:97-104.
31. Tapia Granados JA. 1997. On the terminology and dimensions of incidence. J. Clin. Epidemiol. 50:891- 897.
32. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. 2000. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob. Agents Chemother. 44: 1680-1685.
33. Tjitra E, Hasugian A, Siswantoro H, Prasetyorini B, Ekowatiningsih R, Yusnita EA, Purnamasari T, Driyah S, Salwati E, Nurhayati Yuwarni E, Januar L, Labora J, Wijayanto B, Amansyah F, Dedang TA, Purnama A, Trihono. 2012. Efficacy and safety of artemisinin-naphthoquine versus dihydroartemisinin-piperaquine in adult patients with uncomplicated malaria: a multi-centre study in Indonesia. Malar. J. 11:153.
34. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, Lindegardh N, Singhasivanon P, White NJ, Nosten F. 2011. Dihydroartemisinin- piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin. Infect. Dis. 53:977-984.
35. Hamedi Y, Safa O, Zare S, Tan-ariya P, Kojima S, Looareesuwan S. 2004. Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand. Southeast Asian J. Trop. Med. Public Health 35:570 -574.
36. Krudsood S, Tangpukdee N, Wilairatana P, Phophak N, Baird JK, Brittenham GM, Looareesuwan S. 2008. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 78:736 -740.
37. Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, Wignall FS, Hoffman SL. 1997. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am. J. Trop. Med. Hyg. 56:621- 626.
38. Ehrman FC, Ellis JM, Young MD. 1945. Plasmodium vivax Chesson strain. Science 101:377.
39. Collins WE, Jeffery GM. 1996. Primaquine resistance in Plasmodium vivax. Am. J. Trop. Med. Hyg. 55:243-249.
40. Dow GS, Gettayacamin M, Hasukjariya P, Imbersin R, Komcharoen S, Sattabangkot J, Kyle D, Milhous W, Cozens S, Kenworthy D, Miller A, Veazey J, Ohrt C. 2011. Radical curative efficacy of tafenoquine combination regimens in Plasmodium cynomolgi-infected rhesus monkeys (Macaca mulatta). Malar. J. 10:212.
41. Tarning J, Rijken MJ, McGready R, Phyo AP, Hanpithakpong W, Day NP, White NJ, Nosten F, Lindegardh N. 2012. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob. Agents Chemother. 56:1997-2007.
42. Cooper WC, Myatt AV, Hernandez T, Jeffery GM, Coatney GR. 1953. Studies in human malaria. XXXI. Comparison of primaquine, isopentaquine, SN-3883, and pamaquine as curative agents against Chesson strain vivax malaria. Am. J. Trop. Med. Hyg. 2:949 -957.
43. Baird JK. 2004. Chloroquine resistance in Plasmodium vivax. Antimicrob. Agents Chemother. 48:4075- 4083.